For people recovering from surgery to remove low rectal cancer, a combined program addressing mental health, sleep, and nutrition leads to less anxiety and depression, better bowel and sexual function, lower levels of inflammation, and higher survival rates at two years compared to standard postoperative care. This finding is from the abstract summary - full study details were not available.
Claim Context
In patients undergoing curative resection for low rectal cancer, a multimodal integrative program combining psychosocial, sleep, and nutritional support significantly reduces psychological distress, improves anorectal and sexual function, lowers postoperative inflammatory markers, and increases two-year disease-free and overall survival compared to standard ERAS-based care.
“At 24 months, intervention patients showed greater reductions in BDI-II (-5.2), BAI (-3.8), and PSQI (-2.9), lower major LARS prevalence (28.7 % vs 46.2 %), and higher IIEF-5/FSFI scores. Postoperative CRP, IL-6, and TNF-α were lower (p < 0.001). Two-year DFS and OS were 90.3 % vs 79.2 % (p = 0.028) and 93.6 % vs 82.5 % (p = 0.019), respectively.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether this specific multimodal intervention consistently improves psychological, functional, inflammatory, and survival outcomes across diverse populations and healthcare settings after low rectal cancer resection.
A systematic review and meta-analysis of all randomized controlled trials comparing integrated psychosocial-sleep-nutrition programs to standard ERAS care in adults undergoing curative resection for low rectal cancer, with standardized outcome measures for depression (BDI-II), anxiety (BAI), sleep (PSQI), anorectal function (LARS), sexual function (IIEF-5/FSFI), inflammatory markers (CRP, IL-6, TNF-α), and survival (DFS/OS) at 24 months, including subgroup analyses by age, tumor stage, and center.
That the intervention directly causes improvements in survival and functional outcomes by isolating its effects from confounding variables through randomization and control.
A multicenter, double-blind, placebo-controlled RCT with 500+ adults aged 40–75 undergoing curative low rectal resection, randomized to either the full integrative program (structured counseling, sleep hygiene protocol, personalized nutrition plan) or identical standard care with sham interventions (e.g., non-specific supportive chats, placebo supplements, dummy sleep tracking), measuring BDI-II, BAI, PSQI, LARS, IIEF-5/FSFI, CRP, IL-6, TNF-α, DFS, and OS at 24 months.
Whether the intervention leads to sustained improvements in survival and function in real-world clinical practice over time, accounting for patient adherence and comorbidities.
A prospective cohort study following 1000+ patients undergoing low rectal cancer resection in community hospitals, tracking those who receive the full integrative program versus those who receive partial or no support, with monthly assessments of psychological, functional, and inflammatory markers and annual survival tracking for five years.
Whether patients who survived beyond two years were more likely to have received the integrative program compared to those who did not, adjusting for baseline risk factors.
A case-control study comparing 200 patients who died within two years post-surgery to 200 matched survivors, assessing prior exposure to the full integrative program, controlling for age, tumor stage, comorbidities, and surgical complexity.
Whether patients reporting higher adherence to psychosocial, sleep, and nutritional practices at 24 months are more likely to have better functional and survival outcomes at that single time point.
A cross-sectional survey of 500 patients two years after low rectal cancer resection, measuring self-reported adherence to the intervention components and correlating them with current functional status (LARS, IIEF-5/FSFI), inflammatory markers, and survival status.